Thomas Malcolm

Dr. Malcolm brings nearly 25 years of combined experience in genetic regulation of virally infected human cells and human cancers, gene editing of infectious diseases, chimeric antigen receptor therapeutic development, targeted delivery of therapeutic biomolecules and extracellular vesicle science to the executive team of Caravan Biologix Inc. Dr. Malcolm founded Caravan Biologix to develop the novel mini-CAR and mini-VAN technologies to resolve the challenges associated with CAR cell therapies in treating solid tumor cancers as well as the delivery of biologic therapeutics to treat an abundance of human diseases, respectively.

Dr. Malcolm also serves as the COO and Board Member for Kermode Biotechnologies Inc., a multinational company that he co-founded in 2019 that is dedicated to developing vaccines and therapeutics for protecting and treating livestock animals from the economically devastating African Swine Fever Virus and Swine Influenza Virus.